|
|
||||||||
2 Gene Exhibit a Nonhealing Phenotype to Leishmania major Infection Despite Intact IL-12 Signaling

*
Mucosal Immunity Section and
Clinical Immunology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892
In BALB/c mice infected with Leishmania major, early
secretion of IL-4 leads to a Th2-type response and nonhealing. We
explored the role of IL-4-induced down-regulation of the IL-12R
2
chain in the establishment of this Th2 response. First, we showed that
the draining lymph nodes of resistant C57BL/6 mice infected with
L. major were enriched in CD4+/IL-12R
2
chain+ cells producing IFN-
. Next, we demonstrated that
BALB/c background mice bearing an IL-12R
2-chain transgene manifested
a nonhealing phenotype similar to wild-type littermates despite the
persistence of their ability to undergo STAT4 activation. Finally, we
found that such transgenic mice display more severe infection than
wild-type littermates when treated with IL-12 7 days after infection,
and under this condition, the mice display increased
Leishmania Ag-induced IL-4 secretion. These studies
indicate that although CD4+/IL-12R
2 chain+ T
cells are important components of the Th1 response, maintenance of
IL-12R
2 chain expression is not sufficient to change a Th2 response
to a Th1 response in vivo and thus to allow BALB/c mice to heal
L. major infection.
This article has been cited by other articles:
![]() |
A. P. Nigg, S. Zahn, D. Ruckerl, C. Holscher, T. Yoshimoto, J. M. Ehrchen, F. Wolbing, M. C. Udey, and E. von Stebut Dendritic Cell-Derived IL-12p40 Homodimer Contributes to Susceptibility in Cutaneous Leishmaniasis in BALB/c Mice J. Immunol., June 1, 2007; 178(11): 7251 - 7258. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Charoenvit, G. T. Brice, D. Bacon, V. Majam, J. Williams, E. Abot, H. Ganeshan, M. Sedegah, D. L. Doolan, D. J. Carucci, et al. A Small Peptide (CEL-1000) Derived from the {beta}-Chain of the Human Major Histocompatibility Complex Class II Molecule Induces Complete Protection against Malaria in an Antigen-Independent Manner Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2455 - 2463. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. von Stebut, J. M. Ehrchen, Y. Belkaid, S. L. Kostka, K. Molle, J. Knop, C. Sunderkotter, and M. C. Udey Interleukin 1{alpha} Promotes Th1 Differentiation and Inhibits Disease Progression in Leishmania major-susceptible BALB/c Mice J. Exp. Med., July 21, 2003; 198(2): 191 - 199. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kropf, S. Herath, R. Klemenz, and I. Muller Signaling through the T1/ST2 Molecule Is Not Necessary for Th2 Differentiation but Is Important for the Regulation of Type 1 Responses in Nonhealing Leishmaniamajor Infection Infect. Immun., April 1, 2003; 71(4): 1961 - 1971. [Abstract] [Full Text] |
||||
![]() |
G.-X. Zhang, B. Gran, S. Yu, J. Li, I. Siglienti, X. Chen, M. Kamoun, and A. Rostami Induction of Experimental Autoimmune Encephalomyelitis in IL-12 Receptor-{beta}2-Deficient Mice: IL-12 Responsiveness Is Not Required in the Pathogenesis of Inflammatory Demyelination in the Central Nervous System J. Immunol., February 15, 2003; 170(4): 2153 - 2160. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, U. M. Padigel, P. Scott, and J. P. Farrell Combined Treatment with Interleukin-12 and Indomethacin Promotes Increased Resistance in BALB/c Mice with Established Leishmania major Infections Infect. Immun., October 1, 2002; 70(10): 5715 - 5720. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Aguilar Torrentera, J. D. Laman, M. Van Meurs, L. Adorini, E. Muraille, and Y. Carlier Endogenous Interleukin-12 Is Critical for Controlling the Late but Not the Early Stage of Leishmania mexicana Infection in C57BL/6 Mice Infect. Immun., September 1, 2002; 70(9): 5075 - 5080. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gorelik, S. Constant, and R. A. Flavell Mechanism of Transforming Growth Factor {beta}-induced Inhibition of T Helper Type 1 Differentiation J. Exp. Med., June 3, 2002; 195(11): 1499 - 1505. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |